;
Skip to main content
Home > SciBX > Translational Notes

Chronological Index of : Translational Notes

 Current Issue
  • New CAR shopping

    Kite Pharma's Arie Belldegrun says that target selection is the most important and difficult aspect of early stage CAR T cell research.

    Published on 10/16/2014
  • Translational tidbits

    The NIH pledges almost $100 million for big data programs; CRUK and MedImmune join forces in Cambridge, U.K.; UNC's research center gets a lifetime endowment of $15 million per year; MS benefits from a new PPP.

    Published on 10/16/2014
  • Table 1: Selected public-private partnerships for September 2014

    Translational tidbits Table 1. Selected public-private partnerships for September 2014. It was another quiet month for public-private partnerships. The NIH announced a series of 6-year awards totaling about $64 …

    Published on 10/16/2014
  • Figure 1: New kinase inhibitors approved in U.S. by year

    Translational Notes: A conversation with Jeffrey Settleman Figure 1. New kinase inhibitors approved in U.S. by year. Counts for 2014 exclude Chugai Pharmaceutical Co. Ltd.'s Alecensa alectinib, a small molecule …

    Published on 10/2/2014
  • Table 1: Piloting progress in MS

    Translational Notes: Progressive thinking in MS Table 1. Piloting progress in MS. In the first stage of a 5-year initiative, the International Progressive MS Alliance has awarded approximately €75,000 ($95,640) to …

    Published on 10/2/2014
  • A conversation with Jeffrey Settleman

    SciBX spoke with Genentech's Jeffrey Settleman about resistance mechanisms against kinase inhibitors used to treat cancer and what should be done to tackle the problem.

    Published on 10/2/2014
  • Progressive thinking in MS

    The International Progressive MS Alliance is pushing for advances in progressive MS-an understudied form of the disease-by funding 22 projects in the pilot phase of its 5-year, €22 million ($28 million) initiative.

    Published on 10/2/2014
  • Canadian accelerant

    Two Canadian venture firms and a government-funded program have launched Canada's first national health science accelerator, Accel-Rx, to reignite local VC interest in funding early stage biotechs.

    Published on 9/25/2014
  • The FDA's push for better biomarkers

    The FDA is calling on stakeholders to help define a path for validating and approving biomarkers to enable their use in drug development.

    Published on 9/18/2014
  • Translational tidbits

    The FDA reviews the status of RNA sequencing; Serono builds on its lupus partnerships; Genomics England receives over £300 million ($500 million) in new investments; a roundup of recent public-private partnerships.

    Published on 9/18/2014
  • Table 1: Selected public-private partnerships for August 2014

    Translational Notes: Translational tidbits Table 1. Selected public-private partnerships for August 2014. Public-private partnership activity was sparse in August. Most notable was U.K. Prime Minister David Cameron's…

    Published on 9/18/2014
  • Figure 1: Investing in the brain

    Translational Notes: Buckets of money for the brain Figure 1. Investing in the brain. (I) Number of public-private partnerships (PPPs) announced for neurology or cancer indications. Data include double counting as …

    Published on 9/11/2014
  • Figure 2: Neurology indications for PPPs formed since 2011

    Translational Notes: Buckets of money for the brain Figure 2. Neurology indications for PPPs formed since 2011. Data include double counting as some PPPs include multiple indications. Percentages are out of the total…

    Published on 9/11/2014
  • A conversation with Miguel Barbosa

    SciBX talked with Janssen's VP and head of immunology research and scientific partnership strategy about rethinking how to attack inflammatory bowel disease.

    Published on 9/11/2014
  • Buckets of money for the brain

    A few years ago, many companies threw in the towel on neurological diseases because poor understanding of their biology made R&D too risky. The field is finally receiving increased private and public funding, but some …

    Published on 9/11/2014
  • Table 1: Druggable projects

    Translational Notes: Funding forgotten proteins Table 1. Druggable projects. The NIH has allocated $5.8 million to fund 7 research projects that explore the biology of GPCRs, ion channels, kinases and nuclear …

    Published on 9/4/2014
  • Table 1: Allied Minds startups based in the life sciences

    Translational Notes: Meeting of the minds Table 1. Allied Minds startups based in the life sciences. Source: Allied Minds Startup Technology concept Products Origin of technology Biotectix LLC Next-generation …

    Published on 9/4/2014
  • Funding forgotten proteins

    A new NIH program is looking to fund understudied members of druggable protein classes by supporting exploratory projects at risk of being passed over because of a lack of preliminary data.

    Published on 9/4/2014
  • Meeting of the minds

    Allied Minds has partnered with Bristol-Myers Squibb to form Allied-Bristol Life Sciences LLC and can now add therapeutics to its portfolio of academia-based startups.

    Published on 9/4/2014
  • Table 1: Comparison of current awards to support nontraditional funding methods

    Translational Notes: Getting researchers off the grant treadmill Table 1. Comparison of current awards to support nontraditional funding methods. Source: NIH NIH Director's Awards National Cancer Institute …

    Published on 8/28/2014
  • Getting researchers off the grant treadmill

    The National Cancer Institute has created a generous seven-year award designed to ease the grant-writing burden for 'outstanding investigators'. Now the institute needs to ensure that the program is not just easier …

    Published on 8/28/2014
  • Industrial strength for Sanford-Burnham

    GSK executive Perry Nisen has joined Sanford-Burnham as CEO and plans to apply his industry know-how to accelerate drug development at the institute.

    Published on 8/28/2014
  • AstraZeneca taps the Cambridge wellspring

    AstraZeneca has unveiled plans for its R&D center and global headquarters in Cambridge, U.K. -- the next major step in the pharma's strategy to improve pipeline productivity to help it recover growth and regain ground …

    Published on 8/21/2014
  • Translational tidbits

    Astellas and Cancer Research UK team up to tackle autophagy in pancreatic cancer; the NIH bets big on bioelectronic therapeutics; a roundup of public-private partnerships.

    Published on 8/14/2014
  • Table 1: Selected public-private partnerships for July 2014

    Translational Notes: Translational tidbits Table 1. Selected public-private partnerships for July 2014. In July, Intellimedix Inc. and Pfizer Inc. (NYSE:PFE) partnered with the Epilepsy Foundation to develop drug …

    Published on 8/14/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993